On May 14th, Zhu Jingjin, Secretary of the Party Committee and Vice President of China Biology, and Zhang Yuntao, Vice President and Chief Scientist, and his delegation visited Zhongsheng Fu Nuojian Biotechnology (Shanghai) Co., Ltd. for investigation. Dr. Jia Weiguo, Chief Scientist of Biomedicine, and Huang Hongwei, General Manager, reported the company's basic situation, scientific research progress, and talent team building.

▲Zhu Jingjin (middle) and Zhang Yuntao (left) visit the Zhongsheng Fu Nuojian laboratory

During the discussion and exchange with the scientists and management backbones of Zhongsheng Renovation, Zhu Jingjin reviewed the achievements of China Biotech in the fight against the new crown epidemic. He said that the development of Sino Biotech must conform to the overall strategic plan of China Biotech, adhere to the corporate philosophy of "caring for life and care for health", implement the value of "love and responsibility", and develop products that protect human life and health. Zhongsheng Fu Nuojian has the potential and advantages to target the world's most cutting-edge biotechnology, and must further strengthen its strength to build a high-level technology platform and R&D center. He emphasized that in the scientific and technological research, which procedures need to go through the green channel, and which need to be coordinated by China's biology, they should be resolved in a timely manner. Zhongsheng Fu Nuojian must seize the opportunity, and on the premise of respecting the laws of scientific research, do everything possible to speed up the research and development of projects under research, and produce products early to benefit the people.

Zhongsheng Fu Nuojian is a subsidiary of China Biotech Holdings, which is developing and introducing a series of products such as a new generation of new crown vaccines, oncolytic viruses, antibodies, and personalized precision diagnosis and treatment.

Source: China Bio

Disclaimer: Please contact us if it involves content, copyright or other issues.